Cyclacel Pharmaceuticals (CYCC) Competitors $0.32 +0.04 (+13.20%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$0.32 +0.00 (+1.39%) As of 09:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CYCC vs. VIRI, ADAG, ORMP, OPTN, HLVX, CCCC, ANIX, COYA, MIST, and GNLXShould you be buying Cyclacel Pharmaceuticals stock or one of its competitors? The main competitors of Cyclacel Pharmaceuticals include Virios Therapeutics (VIRI), Adagene (ADAG), Oramed Pharmaceuticals (ORMP), OptiNose (OPTN), HilleVax (HLVX), C4 Therapeutics (CCCC), Anixa Biosciences (ANIX), Coya Therapeutics (COYA), Milestone Pharmaceuticals (MIST), and Genelux (GNLX). These companies are all part of the "pharmaceutical products" industry. Cyclacel Pharmaceuticals vs. Its Competitors Virios Therapeutics Adagene Oramed Pharmaceuticals OptiNose HilleVax C4 Therapeutics Anixa Biosciences Coya Therapeutics Milestone Pharmaceuticals Genelux Virios Therapeutics (NASDAQ:VIRI) and Cyclacel Pharmaceuticals (NASDAQ:CYCC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, community ranking, media sentiment, earnings, dividends and risk. Do analysts recommend VIRI or CYCC? Virios Therapeutics currently has a consensus price target of $3.00, suggesting a potential downside of 39.15%. Given Virios Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Virios Therapeutics is more favorable than Cyclacel Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Cyclacel Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has higher valuation & earnings, VIRI or CYCC? Virios Therapeutics has higher earnings, but lower revenue than Cyclacel Pharmaceuticals. Virios Therapeutics is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirios TherapeuticsN/AN/A-$5.30M-$0.27-18.26Cyclacel Pharmaceuticals$14K506.11-$22.56M-$56.00-0.01 Does the media prefer VIRI or CYCC? In the previous week, Cyclacel Pharmaceuticals had 1 more articles in the media than Virios Therapeutics. MarketBeat recorded 1 mentions for Cyclacel Pharmaceuticals and 0 mentions for Virios Therapeutics. Cyclacel Pharmaceuticals' average media sentiment score of 1.87 beat Virios Therapeutics' score of 0.00 indicating that Cyclacel Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Virios Therapeutics Neutral Cyclacel Pharmaceuticals Very Positive Is VIRI or CYCC more profitable? Virios Therapeutics has a net margin of 0.00% compared to Cyclacel Pharmaceuticals' net margin of -18,150.00%. Virios Therapeutics' return on equity of -130.33% beat Cyclacel Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Virios TherapeuticsN/A -130.33% -115.00% Cyclacel Pharmaceuticals -18,150.00%-1,901.11%-188.23% Does the MarketBeat Community prefer VIRI or CYCC? Cyclacel Pharmaceuticals received 184 more outperform votes than Virios Therapeutics when rated by MarketBeat users. However, 50.00% of users gave Virios Therapeutics an outperform vote while only 44.74% of users gave Cyclacel Pharmaceuticals an outperform vote. CompanyUnderperformOutperformVirios TherapeuticsOutperform Votes350.00% Underperform Votes350.00% Cyclacel PharmaceuticalsOutperform Votes18744.74% Underperform Votes23155.26% Which has more risk & volatility, VIRI or CYCC? Virios Therapeutics has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500. Comparatively, Cyclacel Pharmaceuticals has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500. Do insiders and institutionals have more ownership in VIRI or CYCC? 9.1% of Virios Therapeutics shares are owned by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. 12.2% of Virios Therapeutics shares are owned by company insiders. Comparatively, 96.9% of Cyclacel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryVirios Therapeutics beats Cyclacel Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Get Cyclacel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYCC vs. The Competition Export to ExcelMetricCyclacel PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.09M$6.85B$5.57B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-0.038.7827.1420.06Price / Sales506.11255.49419.32157.08Price / CashN/A65.8538.2534.64Price / Book0.556.557.064.70Net Income-$22.56M$143.93M$3.23B$247.88M7 Day Performance-47.83%3.84%2.83%2.63%1 Month Performance-91.21%11.20%9.02%6.36%1 Year Performance-98.85%4.18%31.36%14.05% Cyclacel Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYCCCyclacel Pharmaceuticals1.1994 of 5 stars$0.32+13.2%N/A-98.9%$7.09M$14K-0.0314High Trading VolumeVIRIVirios TherapeuticsN/A$5.18-2.1%$3.00-42.1%+2,104.8%$99.76MN/A-19.195ADAGAdagene2.7362 of 5 stars$2.09+7.5%$8.00+283.7%-32.0%$98.22M$103.20K0.00260Positive NewsORMPOramed Pharmaceuticals1.8546 of 5 stars$2.38+1.7%N/A+7.7%$97.22M$2M21.6410Positive NewsOPTNOptiNose1.8144 of 5 stars$9.60flat$9.00-6.3%N/A$97.22M$81.86M-2.29190HLVXHilleVax3.2589 of 5 stars$1.93+3.2%$3.00+55.4%-86.7%$96.77MN/A-0.6220Positive NewsCCCCC4 Therapeutics2.2222 of 5 stars$1.33+6.4%$12.00+802.3%-68.7%$94.44M$39.78M-0.78150Positive NewsGap UpANIXAnixa Biosciences3.4673 of 5 stars$2.89+12.5%$9.00+211.4%+30.2%$93.05M$210K-7.415Analyst ForecastGap UpHigh Trading VolumeCOYACoya Therapeutics2.2204 of 5 stars$5.55+4.1%$17.00+206.3%-29.6%$92.82M$3.69M-8.546News CoveragePositive NewsAnalyst ForecastMISTMilestone Pharmaceuticals2.4055 of 5 stars$1.73+6.8%$17.00+882.7%+19.4%$92.49M$1M-2.1430Positive NewsGNLXGenelux1.2619 of 5 stars$2.45+1.2%$17.75+624.5%+7.7%$92.45M$8K-2.5810News Coverage Related Companies and Tools Related Companies Virios Therapeutics Competitors Adagene Competitors Oramed Pharmaceuticals Competitors OptiNose Competitors HilleVax Competitors C4 Therapeutics Competitors Anixa Biosciences Competitors Coya Therapeutics Competitors Milestone Pharmaceuticals Competitors Genelux Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYCC) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclacel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CYCC Stock Free CYCC Stock Alerts